Talis Biomedical Corporation TLIS
Set alert
2.84 USD +2.84 —
Day range unavailable
52-week range unavailable
- YTD
- 0.00%
- 1 year
- +71.08%
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 3.23M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.08
- Beta
- 1.56
- Short ratio
- 0.59
- Inst. own
- 55.06%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 24, 2024
- 50-d avg
- 1.89
- 200-d avg
- 6.59
- 1y target
- 0.00
Financial health
Altman Z-Score
-12.27 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Valuation
P/E -0.2×
FY 2018 5y median -0.5× FY 2023
P/S 32.9×
FY 2018 5y median 11.1× FY 2023
P/B 0.2×
FY 2018 5y median 0.1× FY 2023
P/FCF -0.3×
FY 2018 5y median -0.5× FY 2023
EV/EBITDA 0.7×
FY 2018 5y median 0.7× FY 2023
EV/Sales -106×
FY 2018 5y median -15.6× FY 2023
FCF Yield -396.8%
FY 2018 5y median -191.8% FY 2023
Profitability
Gross Margin 90.0%
FY 2018 5y median 87.4% FY 2023
Operating Margin -16217.2%
FY 2018 5y median -2441.2% FY 2023
Net Margin -15050.2%
FY 2018 5y median -2324.6% FY 2023
ROE -89.7%
FY 2018 5y median -81.4% FY 2023
ROIC -72.3%
FY 2018 5y median -72.3% FY 2023
ROA -65.5%
FY 2018 5y median -66.8% FY 2023
Growth (YoY)
Revenue -88.7%
FY 2018 FY 2023
Operating Income 40.7%
FY 2018 FY 2023
EPS (diluted) 46.4%
FY 2018 FY 2023
Free Cash Flow 47.2%
FY 2018 FY 2023
Financial Health
Current Ratio 8.9×
FY 2018 5y median 10.5× FY 2023
Quick Ratio 8.9×
FY 2018 5y median 10.5× FY 2023
Debt / Equity 0.3×
FY 2018 5y median 0.1× FY 2023
Net Debt / EBITDA 0.9×
FY 2018 5y median 0.9× FY 2023
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2023
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2023
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2023
Annual · latest fiscal year ends 2023-12-31
